AxoGen (AXGN) Tops Q2 EPS by 11c, provides guidance

AxoGen (NASDAQ: AXGN) reported Q2 EPS of $0.05, $0.11 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $47.91 million versus the consensus estimate of $43.37 million.

GUIDANCE:

AxoGen sees FY2024 revenue of $182-186 million, versus the consensus of $178.8 million.
"We are also adjusting our gross margin guidance for the full year to be in the range of 74% to 76%. Additionally, we reiterate that we expect to be net cash flow positive cumulatively for the period from April 1st through year end."

For earnings history and earnings-related data on AxoGen (AXGN) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• FDA grants rolling review for Palvella's rapamycin NDA for rare condition
• Labcorp makes RNA-based colorectal cancer home test available nationwide